Severity of coeliac disease and clinical management study when using a non-metabolised medication: a phase I pharmacokinetic study.

ABSTRACT:

Objective

The non-metabolised antihistamine fexofenadine has oral absorption resulting from transporter activity. Uptake by enterocyte organic anion transporting polypeptides and efflux by an ATP-binding cassette transporter (P-glycoprotein) are primary determinants. Coeliac disease-mediated lesions to the small intestinal mucosa may alter oral absorption of the drug probe, fexofenadine.

Design

A phase I, open-label, single-dose, pharmacokinetic study SETTING: London, Ontario, Canada PARTICIPANTS: Patients with coeliac disease (n=41) with positive serology and healthy individuals (n=48).

Main outcome measures

Patients with coeliac disease-duodenal histology and oral fexofenadine pharmacokinetics within a 3-week period. Healthy individuals-oral fexofenadine pharmacokin

SUBMITTER: Chretien ML 

PROVIDER: S-EPMC9972437 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature